Kala Bio R&D Spending Growth & History (KALA)
Kala Bio's r&d spending was $18.8M for fiscal 2025.
View full Kala Bio company overviewKala Bio annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18.8M | −$3.3M | −15.00% |
| 2024 | 2024-12-31 | $22.1M | $3.5M | +18.87% |
| 2023 | 2023-12-31 | $18.6M | $933,000 | +5.29% |
| 2022 | 2022-12-31 | $17.7M | $6.1M | +53.30% |
| 2021 | 2021-12-31 | $11.5M | −$6.8M | −37.25% |
| 2020 | 2020-12-31 | $18.4M | −$8.9M | −32.71% |
| 2019 | 2019-12-31 | $27.3M | −$2.0M | −6.88% |
| 2018 | 2018-12-31 | $29.3M | $282,000 | +0.97% |
| 2017 | 2017-12-31 | $29.0M | $4.0M | +15.90% |
| 2016 | 2016-12-31 | $25.0M | $13.6M | +119.90% |
| 2015 | 2015-12-31 | $11.4M | — | — |
Kala Bio quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $59,000 | −$6.2M | −99.05% |
| Q1 2026 | 2026-03-31 | $61,000 | −$6.0M | −98.99% |
| Q4 2025 | 2025-12-31 | $366,000 | −$4.9M | −93.04% |
| Q3 2025 | 2025-09-30 | $6.1M | $959,000 | +18.56% |
| Q2 2025 | 2025-06-30 | $6.2M | $915,000 | +17.21% |
| Q1 2025 | 2025-03-31 | $6.1M | −$296,000 | −4.66% |
| Q4 2024 | 2024-12-31 | $5.3M | $540,000 | +11.45% |
| Q3 2024 | 2024-09-30 | $5.2M | −$386,000 | −6.95% |
| Q2 2024 | 2024-06-30 | $5.3M | $1.0M | +24.29% |
| Q1 2024 | 2024-03-31 | $6.4M | $2.3M | +57.36% |
| Q4 2023 | 2023-12-31 | $4.7M | $1.4M | +41.98% |
| Q3 2023 | 2023-09-30 | $5.6M | $163,000 | +3.02% |
| Q2 2023 | 2023-06-30 | $4.3M | −$195,000 | −4.36% |
| Q1 2023 | 2023-03-31 | $4.0M | −$430,000 | −9.63% |
| Q4 2022 | 2022-12-31 | $3.3M | $909,000 | +37.66% |
| Q3 2022 | 2022-09-30 | $5.4M | $2.5M | +87.12% |
| Q2 2022 | 2022-06-30 | $4.5M | $1.4M | +44.57% |
| Q1 2022 | 2022-03-31 | $4.5M | $1.3M | +42.87% |
| Q4 2021 | 2021-12-31 | $2.4M | −$983,000 | −28.94% |
| Q3 2021 | 2021-09-30 | $2.9M | −$587,000 | −16.93% |
| Q2 2021 | 2021-06-30 | $3.1M | −$3.0M | −48.88% |
| Q1 2021 | 2021-03-31 | $3.1M | −$2.3M | −42.47% |
| Q4 2020 | 2020-12-31 | $3.4M | −$2.7M | −44.66% |
| Q3 2020 | 2020-09-30 | $3.5M | −$3.6M | −50.95% |
| Q2 2020 | 2020-06-30 | $6.1M | −$1.1M | −14.84% |
| Q1 2020 | 2020-03-31 | $5.4M | −$1.5M | −21.91% |
| Q4 2019 | 2019-12-31 | $6.1M | −$3.1M | −33.56% |
| Q3 2019 | 2019-09-30 | $7.1M | $43,000 | +0.61% |
| Q2 2019 | 2019-06-30 | $7.1M | −$260,000 | −3.53% |
| Q1 2019 | 2019-03-31 | $7.0M | $1.3M | +23.02% |
| Q4 2018 | 2018-12-31 | $9.2M | $3.4M | +57.11% |
| Q3 2018 | 2018-09-30 | $7.0M | $9,000 | +0.13% |
| Q2 2018 | 2018-06-30 | $7.4M | −$703,000 | −8.71% |
| Q1 2018 | 2018-03-31 | $5.7M | −$2.4M | −29.63% |
| Q4 2017 | 2017-12-31 | $5.9M | — | — |
| Q3 2017 | 2017-09-30 | $7.0M | −$1.2M | −15.00% |
| Q2 2017 | 2017-06-30 | $8.1M | $2.1M | +35.65% |
| Q1 2017 | 2017-03-31 | $8.0M | — | — |
| Q3 2016 | 2016-09-30 | $8.3M | — | — |
| Q2 2016 | 2016-06-30 | $6.0M | — | — |
Kala Bio r&d spending trends
Over the last five fiscal years, Kala Bio's r&d spending increased from $18.4M to $18.8M, a change of $428,000. The latest reported quarter, Q2 2026, shows $59,000.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kala Bio source filings ↗